|Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents - Monitor Patents|
USPTO Class 530 | Browse by Industry: Previous - Next | All
12/2010 | Recent | 13: May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof December patent applications/inventions, industry category 12/10Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 12/30/2010 > patent applications in patent subcategories. patent applications/inventions, industry category
20100331518 - Ifbm's to promote the specific attachment of target analytes to the surface of orthopedic implants: The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that... Agent: Laura L.kiefer Affinergy, Inc.
20100331519 - Ifbm's to promote the specific attachment of target analytes to the surface of orthopedic implants: The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that... Agent: Laura L.kiefer Affinergy, Inc.
20100331520 - Metastin derivatives and use thereof: The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotrophic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids in the metastin derivative of... Agent: Edwards Angell Palmer & Dodge LLP
20100331521 - Controlled polymerisation process: The present invention relates to a controlled metathesis-driven polymerisation process which is particularly useful for the synthesis of biological polymers such as peptides and polymers. The invention also provides metathesisable supports, groups and linkers for use in the process.... Agent: Marshall, Gerstein & Borun LLP
20100331522 - Capture and elution of bio-analytes via beads that are used to disrupt specimens: Lysing may include agitating a specimen in a chamber along with a medium that includes a particulate lysing material that has an affinity for a biological material. Lysing material may include beads or other material which may be coated that facilitates binding. The medium may include a fluid with a... Agent: Seed Intellectual Property Law Group PLLC
20100331523 - Heterologous protein production using the twin arginine translocation pathway: Provided are means for evaluating and identifying putative substrates of the twin arginine translocation (Tat) secretory pathway in Streptomyces and other bacterial species. Also provided, therefore, are simple ways to express, secrete and purify correctly folded heterologous proteins on a large scale using host microorganisms, such as, Streptomyces and the... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP
20100331524 - Immunomodulatory protein and useful embodiments thereof: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.... Agent: Clark & Elbing LLP
20100331525 - Antitumoral agents with a benzophenanthridine structure and formulations containing them: The use of benzophenanthridine alkaloids and the salts thereof for the preparation of medicaments for the treatment of tumors is disclosed.... Agent: Arent Fox LLP
20100331526 - Capture purification processes for proteins expressed in a non-mammalian system: Methods of purifying proteins expressed in non-mammalian expression systems in a non-native soluble form directly from cell lysate are disclosed. Methods of purifying proteins expressed in non-mammalian expression systems in a non-native limited solubility form directly from a refold solution are also disclosed. Resin regeneration methods are also provided.... Agent: Amgen Inc.
20100331527 - Readily isolated bispecific antibodies with native immunoglobulin format: A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential... Agent: Regeneron Pharmaceuticals, Inc
20100331528 - Isolated antibodies against biologically active leptin-related peptides: The present invention relates to methods and compositions containing novel leptin peptides, preferably for the modulation of body mass (i.e., weight), more specifically for novel diagnostic and therapeutic applications in homeostasis of body weight and adipose tissue mass.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c
20100331529 - Methods for increasing protein polyethylene glycol (peg) conjugation: The present invention relates to highly conjugated proteins and methods for making such proteins. In particular, the present invention relates to methods for linking additional sites to a protein for conjugation with activated polyethylene glycol (PEG) linkers, without denaturing the protein. The invention also relates to highly conjugated proteins with... Agent: Morrison & Foerster LLP
20100331530 - Method for purifying therapeutic proteins by means of multi-stage extraction: Method for purifying therapeutic proteins by multi-stage extractive distillation.... Agent: Gerstenzang, William C. Norris Mclaughlin & Marcus, Pa
20100331531 - Methods for esterifying lignocellulosic material: Methods of making esterified lignocellulosic materials and resulting compositions and articles are disclosed.... Agent: William K. Mcgreevey Eastman Chemical Company12/23/2010 > patent applications in patent subcategories. patent applications/inventions, industry category
20100324262 - Ifbm's to promote the specific attachment of target analytes to the surface of orthopedic implants: The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that... Agent: Laura L.kiefer Affinergy, Inc.
20100324263 - Ifbm's to promote the specific attachment of target analytes to the surface of orthopedic implants: The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that... Agent: Laura L.kiefer Affinergy, Inc.
20100324264 - Synthesis of a peg-6 moiety from commercial low-cost chemicals: The present invention provides novel synthesis's for obtaining a protecting group aminoxy PEG-6 linker from cost effective, and readily available starting materials and chemicals or modified polyethylene glycols. More specifically, a novel synthesis of obtaining a modified Boc-protected aminoxy PEG-6 linker was achieved so that said linker may be attached... Agent: Ge Healthcare, Inc.
20100324265 - Process for the preparation glatiramer acetate (copolymer-1): This invention relates to a convenient and improved process for preparation of glatiramer acetate (copolymer-1) of pharmaceutical grade. The process involves polymerizing N-carboxyanhydrides of tyrosine, alanine, y-benzyl glutamate and &egr;-N-trifluoroacetyllysine in dioxane with diethylamine as initiator to afford protected copolymer-1. Treatment with hydrogen bromide in acetic acid at 35° C.... Agent: Merchant & Gould PC
20100324266 - Photocleavable protecting groups: Novel compounds are provided, which are useful as linking groups in chemical synthesis, preferably in the solid phase synthesis of oligonucleotides and polypeptides. These compounds are generally photolabile and comprise protecting groups which can be removed by photolysis to unmask a reactive group. The protecting group has the general formula... Agent: Cooley LLP Attn: Patent Group
20100324267 - Novel traf family proteins: In accordance with the present invention, there are provided novel TRAF-Protein-Binding-Domain polypeptides (TPBDs). The invention also provides nucleic acid molecules encoding TPBDs, vectors containing these nucleic acid molecules and host cells containing the vectors. The invention also provides antibodies that can specifically bind to invention TPBDs. Such TPBDs and/or anti-TPBD... Agent: Mcdermott, Will & Emery LLP
20100324268 - Multi-oligomeric or multi--polymeric compositions comprising labeled moieties and binding partners: The present invention provides multisignal labeling reagents and these are useful in a number of biochemical applications, including the manufacture of biomolecular probes and their use in detecting or amplifying analyte-specific moieties.... Agent: Enzo Biochem, Inc.
20100324269 - Refolding proteins using a chemically controlled redox state: A method of refolding proteins expressed in non-mammalian cells present in concentrations of 2.0 g/L or higher is disclosed. The method comprises identifying the thiol pair ratio and the redox buffer strength to achieve conditions under which efficient folding at concentrations of 2.0 g/L or higher is achieved and can... Agent: Amgen Inc.
20100324270 - Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma: This invention relates to the polynucleotides and the encoded polypeptides, including novel sequences, of human or non-human primate genes that are amplified in breast and/or other tumor tissues melanoma, as compared to the corresponding normal tissue. The invention also relates to modulators of such polynucleotides and polypeptides, for example, antibodies,... Agent: Five Prime Therapeutics, Inc.
20100324272 - Pancreatic cancer genes: The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality... Agent: Novartis Vaccines And Diagnostics Inc.
20100324271 - Phage-displaying single-chain antibody capable of recognizing non-reduced mannose residue: It is an object of the present invention to provide antibodies which recognize non-reducing mannose residues. The present invention provides antibodies recognizing non-reducing mannose residues, which are obtained through screening of phage-display library of human scFvs by using, as an antigen, Man3-DPPE which is an artificial glycolipid synthesized from mannotriose... Agent: Greenblum & Bernstein, P.L.C12/16/2010 > patent applications in patent subcategories. patent applications/inventions, industry category
20100317827 - method of purifying a peptide: The invention relates, interalia, to the field of purification of peptides, notably cyclic or non-cyclic peptides their analogs or derivatives thereof. More particularly, the invention relates to a simplified and optimized purification process of cyclic peptides from a composition comprising the said peptide and at least one related impurity by... Agent: Harness, Dickey & Pierce, P.L.C
20100317826 - Neoplasm specific antibodies and uses thereof: The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms.... Agent: Pillsbury Winthrop Shaw Pittman LLP
20100317828 - Ifbm's to promote the specific attachment of target analytes to the surface of orthopedic implants: The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that... Agent: Laura L.kiefer Affinergy, Inc.
20100317829 - Ifbm's to promote the specific attachment of target analytes to the surface of orthopedic implants: The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that... Agent: Wayne F. Beyer, Jr.
20100317830 - Bace455, an alternative splice variant of the human beta-secretase: The present invention relates generally to the fields of genetics, biochemistry, medicinal chemistry and medicine. The present invention more particularly discloses the identification of a human gene variant involved in neuropathological conditions, and methods for the diagnosis, prevention and treatment of such diseases and related disorders, as well as for... Agent: Hunton & Williams LLP Intellectual Property Department
20100317831 - Probe compounds for protein tyrosine phosphatase (ptp) and precursors thereof: In Formula (I), A1 and A2 represent amino acids. The amino acids include leucine, phenylalanine, glutamic acid, lysine, alanine, arginine, aspartic acid, asparagine, citrulline, cysteine, cystine, glutamine, glycine, histidine, hydroxyproline, isoleucine, methionine, proline, serine, threonine, tryptophan, valine or a combination thereof. The invention also provides probe compound precursors for protein... Agent: Pai Patent & Trademark Law Firm
20100317832 - Aziridine aldehydes, aziridine-conjugated amino derivatives, aziridine-conjugated biomolecules and processes for their preparation: The present invention applications for same. More particularly, the present invention relates to novel aziridine aldehydes and processes for preparing these novel compounds. The invention also relates to aziridine-conjugated amino derivatives, and processes for preparing the same. Pentacyclic compounds may be prepared using the aziridine aldehydes of the present invention,... Agent: Dann, Dorfman, Herrell & Skillman
20100317833 - Method for the production of dry free-flowing hydrophobin preparations: Method for the production of dry, free-flowing, stable hydrophobin preparations by spraying and drying aqueous hydrophobin solutions, if appropriate comprising additives in a spray device.... Agent: Connolly Bove Lodge & Hutz, LLP
20100317834 - Igg immunoglobulin variants with optimized effector function: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.... Agent: Morgan, Lewis & Bockius, LLP (sf)
20100317835 - Anti-adam-15 antibodies and utilization of the same: A remedy for cancer obtained from a different viewpoint from the viewpoints employed in developing the existing anticancer drugs, i.e., focusing on the intercellular adhesion of cancer cells. Namely, provided is a remedy for cancer with fewer side effects which inhibits the proliferation of cancer cells and the intercellular adhesion... Agent: Morgan Lewis & Bockius LLP
20100317836 - Novel biological substance nesfatin and its related substances and uses thereof: The present invention relates to a novel method of obtaining a factor involved in appetite control and/or body weight control, as well as genes obtained by said method, polypeptides encoded by said genes, or novel polypeptides obtained from the information on polypeptides encoded by said genes as a means for... Agent: Sughrue Mion, PLLC
20100317837 - Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries: The present invention provides a method of identifying novel broadly crossreactive neutralizing monoclonal antibodies using sequential antigen panning of phage display libraries, antibodies obtained in accordance with such a method, as well as fusion proteins and conjugates comprising same, and related isolated or purified nucleic acid molecules, vectors, host cells,... Agent: Leydig, Voit & Mayer, Ltd.12/09/2010 > patent applications in patent subcategories. patent applications/inventions, industry category
20100311944 - Cyclosporine analogue mixtures and their use as immunomodulating agents: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis... Agent: Virtual Law Partners LLP
20100311945 - Hdm2-inhibitor complexes and uses thereof: The present invention includes crystallized HDM2 peptides as well as descriptions of the X-ray diffraction patterns of the crystals. The diffraction patterns allow the three dimensional structure of HDM2 to be determined at atomic resolution so that ligand binding sites on HDM2 can be identified and the interactions of ligands... Agent: Philip S. Johnson Johnson & Johnson
20100311946 - Solid phase peptide for the production of goserelin: The present invention provides a process for the production of goserelin. In particular, the process of the invention allows the use of side chain protecting groups during synthesis of the peptide, and the addition of the azaglycine moiety of the peptide.... Agent: Mallinckrodt Inc.
20100311947 - Polypeptide cleavage process: A palladatepalladium-promoted hydrolytic polypeptide cleavage process which selectively cleaves the polypeptide at a Cys-His cleavage site comprising solubilizing the polypeptide in a reaction mixture comprised of a palladatepalladium promoter dissolved in a high-concentration acidic organic acid solvent.... Agent: Campbell Nelson Whipps, LLC
20100311948 - Fusion protein comprising tumor necrosis factor related apoptosis inducing ligand and integrin ligand and use thereof: Provided is a fusion protein comprising a tumor necrosis factor related apoptosis inducing ligand (TRAIL), integrin ligands of αVβ3 and αVβ5 and a linking peptide. Also provided are the expression method and simple separation and purification process for the production of the fusion protein which is soluble and has high... Agent: Schmeiser, Olsen & Watts
20100311949 - Aligned collagen and method therefor: Compositions and methods of preparing a graft construct comprising aligned collagen fibrils, wherein the construct is anisotropic, are described. The construct is prepared by application of an electrochemical field and a pH gradient to solutions containing collagen. In accordance with this method, collagen aligns at its isoelectric point to form... Agent: Barnes & Thornburg LLP
20100311951 - Abelmoschus manihot (linn.) medicus kernel product for natural nutritional edible and pharmaceutical raw material: An Abelmoschus manihot (Linn.) medius kernel product for natural nutritional edible and pharmaceutical raw material. It is prepared by removing impurity and then cracking the shell of Abelmoschus manihot (Linn.) medius seed; and removing the seed shell to separate the particle powder of the Abelmoschus manihot (Linn.) medius seed, and... Agent: Flash Intellectual Property, Inc. Attn. Cheng-ju Chiang
20100311950 - Soy protein gel and method of producing the same: It is intended to provide a soy protein gel which has such gel properties that have never been obtained hitherto and is excellent in taste and color tone, and a soy protein food taking advantage of the gel properties. It has been found out that gel properties can be modified... Agent: Wenderoth, Lind & Ponack, L.L.P.
20100311952 - Immunoglobulin purification: The current invention reports a method for purifying an immunoglobulin, wherein the method comprises applying an aqueous, buffered solution comprising an immunoglobulin in monomeric and in aggregated form to a cation exchange material under conditions whereby the immunoglobulin in monomeric form does not bind to the cation exchange material, and... Agent: Hoffmann-la Roche Inc. Patent Law Department
20100311953 - Process for purifying proteins: The invention relates to a process for purifying a protein by mixing a protein preparation with a solution having a first salt and a second salt, wherein each salt has a different lyotropic value, and loading the mixture onto a hydrophobic interaction chromatography column. The dynamic capacity of the column... Agent: Amgen Inc.
20100311955 - Humanized anti-human cd34 antibody, the preparation method and uses thereof: The present invention provides a humanized anti-human CD34 antibody and the preparation method thereof. The humanized anti-human CD34 antibody retains the affinity and specificity of its original murine-derived antibody. The antibody can be conjugated with magnetic nano materials to prepare immunomagnetic beads to screen marrow hemopoietic stem cells. It can... Agent: Occhiuti Rohlicek & Tsao, LLP
20100311954 - Optimized proteins that target ep-cam: Humanized Ep-CAM-targeting antibodies and methods of making and using the same are provided.... Agent: Dorsey & Whitney, LLP Intellectual Property Department
20100311956 - Synthetic amphiphiles for membrane protein manipulation: The invention provides amphiphilic compounds and methods for manipulating membrane proteins. Compounds of the invention, for example, the compounds of Formulas I-XIX, can be prepared from readily available starting materials. The amphiphilic compounds can manipulate membrane protein at relatively low concentrations compared to many known detergents. The compounds can be... Agent: Clise, Billion & Cyr, P.A. - Warf12/02/2010 > patent applications in patent subcategories. patent applications/inventions, industry category
20100305303 - Inhibiting agent for inhibition of angiogenesis, a method for preparing the agent, a method for modifying the agent and its use for manufacturing a medicament for treating tumor: a highly efficient antiangiogenesis agent, which is a polypeptide for inhibition of angiogenesis Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro, connected with a polypeptide containing Arg-Gly-Asp on its one end or two ends is provided. The inhibiting agent can be synthesized or gene engineered. It also relates to a physiochemical method for modifying the antiangiogenesis agent.... Agent: Schmeiser, Olsen & Watts
20100305304 - Non-natural proteinaceous scaffold made of three non-covalently associated peptides: The present invention is related to a non-natural, thermodynamically stable, proteinaceous scaffold consisting of three non-covalently associated peptides, wherein each peptide sequence comprises less than fifty amino acid residues and wherein at least 50% of the said residues are substitutable amino acids into at least ten different amino acid residue... Agent: Clark & Elbing LLP
20100305305 - Method for purifying factor viii and von willebrand factor: The purification method includes, starting from a solution selected from (i) a solution containing a mixture of FVIII and FvW, (ii) a solution containing FvW, (iii) a solution derived from a secretion of a non-human animal and (iv) a solution derived from a FVIII-containing plant extract, a step of absorption... Agent: Young & Thompson
20100305306 - Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof: Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not... Agent: Foley And Lardner LLP Suite 500
20100305307 - Human monoclonal antibodies to epidermal growth factor receptor: In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided.... Agent: Amgen Inc.
20100305308 - Lactoferrin: A pure lactoferrin polypeptide containing no more than two metal ions per molecule, or a mixture of the polypeptide and a fragment thereof. The polypeptide or the mixture stimulates skeletal growth and inhibits bone resorption. Also disclosed is a method of treating a bone-related disorder with the polypeptide or the... Agent: Fish & Richardson PC
20100305309 - Nanodiamond particle complexes: The present invention provides various functionalized nanodiamond particles. In particular, the present invention provides soluble complexes of nanodiamond particles and therapeutic agents, for example insoluble therapeutics, anthracycline and/or tetracycline compounds, nucleic acids, proteins, etc.... Agent: Casimir Jones, S.c.
20100305310 - Multi-media affinity column to prevent leaching of ligands: In an affinity-type purification, ligands dissociated from a packed bed that would otherwise leach into the solution containing the species being purified are captured by a second ligand that resides in a porous barrier downstream from the packed bed, the second ligand exhibiting an affinity-type interaction with the dissociated first... Agent: Townsend And Townsend And Crew, LLP
20100305311 - Nanoparticle for separating peptide, method for preparing the same, and method for separating peptide using the same,: Disclosed are nanoparticles for use in the isolation of peptides, a method for producing the nanoparticles, and a method for the isolation of peptides using the nanoparticles. The nanoparticles comprise magnetic nanoparticles and thiol-specific functional groups as first functional groups bound to the surfaces of the magnetic nanoparticles to selectively... Agent: Alston & Bird LLPPrevious industry: Synthetic resins or natural rubbers -- part of the class 520 series
Next industry: Organic compounds -- part of the class -570 series
RSS FEED for 20130516:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents we recommend signing up for free keyword monitoring by email.
FreshPatents.com Support - Terms & Conditions
Results in 0.46097 seconds